Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, 434000, China.
World J Surg Oncol. 2022 Mar 18;20(1):88. doi: 10.1186/s12957-022-02546-w.
To explore the mechanism of E2F transcription Factor 1 (E2F-1)-mediated ataxia-telangiectasia-mutated protein (ATM) in cisplatin (DDP)-resistant nasopharyngeal carcinoma (NPC).
E2F-1 and ATM expression was assessed in DDP-resistant NPC cell lines (CNE2/DDP and HNE1/DDP) and parental cells. Then, DDP-resistant NPC cells were transfected with control shRNA (short hairpin RNA) or E2F-1 shRNAs with or without ATM lentiviral activation particles. The half maximal inhibitory concentration (IC50) was evaluated by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, and the cell cycle and cell proliferation were measured by flow cytometry and EdU staining, respectively. In addition, the expression of genes and proteins was quantified by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and western blotting, respectively.
Both E2F-1 and ATM expression in DDP-resistant NPC cells was much higher than that in parental cells. E2F-1 shRNA reduced ATM expression in DDP-resistant NPC cells, but ATM overexpression had no significant effect on E2F-1. ATM overexpression enhanced DDP resistance in DDP-resistant NPC cells with increased IC50 values, which was reversed by E2F-1 inhibition. Meanwhile, ATM overexpression resulted in upregulation of ABCA2 and ABCA5 in DDP-resistant NPC cells, induced elevations in the transition of the cells into S-phase, and increased cell proliferation with enhanced expression of cyclin E1, CDK2, and Ki67, which was reversed by E2F-1 shRNAs.
Downregulation of E2F-1, possibly by regulating ATM, could block the cell cycle in the G1 phase and reduce the proliferation of CNE2/DDP cells, thereby reversing the resistance of human NPC cells to DDP.
探讨 E2F 转录因子 1(E2F-1)介导的共济失调毛细血管扩张症突变蛋白(ATM)在顺铂(DDP)耐药鼻咽癌(NPC)中的机制。
在 DDP 耐药 NPC 细胞系(CNE2/DDP 和 HNE1/DDP)及其亲本细胞中评估 E2F-1 和 ATM 的表达。然后,用对照 shRNA(短发夹 RNA)或 E2F-1 shRNA 转染 DDP 耐药 NPC 细胞,并用或不用 ATM 慢病毒激活颗粒。通过 3-[4,5-二甲基噻唑-2-基]-2,5 二苯基四氮唑溴盐(MTT)测定半最大抑制浓度(IC50),通过流式细胞术和 EdU 染色分别测定细胞周期和细胞增殖。此外,通过定量逆转录聚合酶链反应(qRT-PCR)和 Western blot 分别定量基因和蛋白的表达。
DDP 耐药 NPC 细胞中 E2F-1 和 ATM 的表达均明显高于亲本细胞。E2F-1 shRNA 降低了 DDP 耐药 NPC 细胞中的 ATM 表达,但 ATM 过表达对 E2F-1 没有显著影响。ATM 过表达增加了 DDP 耐药 NPC 细胞的 DDP 耐药性,导致 IC50 值升高,而 E2F-1 抑制则逆转了这一现象。同时,ATM 过表达导致 DDP 耐药 NPC 细胞中 ABCA2 和 ABCA5 的上调,诱导细胞进入 S 期的转变增加,并通过增强 cyclin E1、CDK2 和 Ki67 的表达增加细胞增殖,而 E2F-1 shRNA 则逆转了这一现象。
下调 E2F-1,可能通过调节 ATM,可阻止 CNE2/DDP 细胞的细胞周期进入 G1 期,并减少其增殖,从而逆转人 NPC 细胞对 DDP 的耐药性。